ADHD pharmacogenetics across the life cycle: New findings and perspectives
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Attention‐deficit/hyperactivity disorder (ADHD) is a complex and heterogeneous disorder, affecting individuals across the life cycle. Although its etiology is not yet completely understood, genetics plays a substantial role. Pharmacological treatment is considered effective and safe for children and adults, but there is considerable inter‐individual variability among patients regarding response to medication, required doses, and adverse events. We present here a systematic review of the literature on ADHD pharmacogenetics to provide a critical discussion of the existent findings, new approaches, limitations, and recommendations for future research. Our main findings are: first, the number of studies continues to grow, making ADHD one of the mental health areas with more pharmacogenetic studies. Second, there has been a focus shift on ADHD pharmacogenetic studies in the last years. There is an increasing number of studies assessing gene–gene and gene–environment interactions, using genome‐wide association approaches, neuroimaging, and assessing pharmacokinetic properties. Third and most importantly, the heterogeneity in methodological strategies employed by different studies remains impressive. The question whether pharmacogenetics studies of ADHD will improve clinical management by shifting from trial‐and‐error approach to a pharmacological regimen that takes into account the individual variability remains unanswered. © 2014 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Merikangas, K. R., He, J.-P., Burstein, M., Swanson, S. A., Avenevoli, S., Cui, L., Benjet, C., Georgiades, K., & Swendsen, J. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.05.017 · Cited by 6,278
Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Faraone, S. V., Greenhill, L. L., Howes, M. J., Secnik, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.716 · Cited by 3,886 · cited 2×
“…is around 5.3–8.7% [Polanczyk et al., 2007a; Merikangas et al., 2010; Kessler et al., 2012; Willcutt, 2012], rates from 2.5% to 4.4% are described for adults [Kessler et al., 2006] reflecting late brain maturation in a 2014 Wiley Periodicals, Inc. 263 proportion of cases [Giedd and Rapoport, 2010].”
BackgroundInfluentialAllelic Variation of Human Serotonin Transporter Gene Expression
Heils, A., Teufel, A., Petri, S., Stöber, G., Riederer, P., Bengel, D., & Lesch, K. P. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66062621.x · Cited by 2,221
The Prevalence of DSM-IV Attention-Deficit/Hyperactivity Disorder: A Meta-Analytic Review
Willcutt, E. G. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0135-8 · Cited by 2,160
Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes
Castellanos, F. X., & Tannock, R. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn896 · Cited by 1,827 · cited 1×
“They are hypothesized to bemore suitable for detecting risk genes because they are genetically less complex by being etiologically closer to biological pathway leading from gene to behavior, diminishing phenotypic heterogeneity [Castellanos and Tannock, 2002].”
BackgroundChen, J., Lipska, B. K., Halim, N., Ma, Q. D., Matsumoto, M., Melhem, S., Kolachana, B. S., Hyde, T. M., Herman, M. M., Apud, J., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/425589 · Cited by 1,675
Castellanos, F. X. (2002) · JAMA · doi:10.1001/jama.288.14.1740 · Cited by 1,646
Detecting gene–gene interactions that underlie human diseases
Cordell, H. J. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2579 · Cited by 1,350
Candidate gene studies of ADHD: a meta-analytic review
Gizer, I. R., Ficks, C., & Waldman, I. D. (2009) · Human Genetics · doi:10.1007/s00439-009-0694-x · Cited by 1,020
Sonuga-Barke, E. J. S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.09.008 · Cited by 962
Greenhill, L. L., Pliszka, S., & Dulcan, M. K. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200202001-00003 · Cited by 927
Pezawas, L., Verchinski, B. A., Mattay, V. S., Callicott, J. H., Kolachana, B. S., Straub, R. E., Egan, M. F., Meyer-Lindenberg, A., & Weinberger, D. R. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2680-04.2004 · Cited by 890
Role of Serotonin in the Paradoxical Calming Effect of Psychostimulants on Hyperactivity
Gainetdinov, R. R., Wetsel, W. C., Jones, S. R., Levin, E. D., Jaber, M., & Caron, M. G. (1999) · Science · doi:10.1126/science.283.5400.397 · Cited by 885
Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants
Asghari, V., Sanyal, S., Buchwaldt, S., Paterson, A., Jovanovic, V., & Van Tol, H. H. M. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.65031157.x · Cited by 858
Structural MRI of pediatric brain development: what have we learned and where are we going?
Giedd, J. N., & Rapoport, J. L. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.040 · Cited by 836
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666
NIGG, J. T., & CASEY, B. J. (2005) · Development and Psychopathology · doi:10.1017/s0954579405050376 · Cited by 593
Scheres, A., Milham, M. P., Knutson, B., & Castellanos, F. X. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.04.042 · Cited by 499
Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis
Faraone, S. V., & Buitelaar, J. (2010) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0054-3 · Cited by 485 · cited 1×
“All of them determine good response in decreasing ADHD symptoms, although their pharmacokinetics are quite different [Faraone and Buitelaar, 2010].”
BackgroundMolecular Genetics of Attention Deficit Hyperactivity Disorder
Faraone, S. V., & Mick, E. (2010) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.12.004 · Cited by 411 · cited 4×
“However, it is known that MPH also blocks efficiently the norepinephrine transporter (NET) [Faraone and Mick, 2010; Hannestad et al., 2010].”
BackgroundInfluentialGaspar, P., Berger, B., Febvret, A., Vigny, A., & Henry, J. P. (1989) · Journal of Comparative Neurology · doi:10.1002/cne.902790208 · Cited by 395 · cited 1×
“Thedopaminebetahydroxylase enzyme (DBH) catalyzes the conversion of dopamine (DA) into norepinephrine (NE) and is expressed within the secretory vesicle [Gaspar et al., 1989].”
BackgroundThe Dopamine Transporter and Attention-Deficit/Hyperactivity Disorder
Madras, B. K., Miller, G. M., & Fischman, A. J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.10.011 · Cited by 393 · cited 1×
“It was postulated that NET could transport dopamine in the prefrontal cortex because dopamine has a greater affinity for NET as compared with its affinity for DAT [Madras et al., 2005; Hannestad et al., 2010].”
BackgroundA review of the biological bases of ADHD: What have we learned from imaging studies?
Durston, S. (2003) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.10079 · Cited by 388
Synaptic plasticity and mood disorders
Duman, R. S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001016 · Cited by 363
Arnsten, A. F., & Dudley, A. G. (2005) · Behavioral and Brain Functions · doi:10.1186/1744-9081-1-2 · Cited by 363
Mill, J., Asherson, P., Browes, C., D'Souza, U., & Craig, I. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.b.10948 · Cited by 341 · cited 1×
“In vitro studies suggested that DATVNTRhas a functional role, with the 10R being associated with higher expression levels of the transporter [Mill et al., 2002; Purper-Ouakil et al., 2008].”
BackgroundCortese, S. (2012) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2012.01.009 · Cited by 335
Reward anticipation and outcomes in adult males with attention-deficit/hyperactivity disorder
Ströhle, A., Stoy, M., Wrase, J., Schwarzer, S., Schlagenhauf, F., Huss, M., Hein, J., Nedderhut, A., Neumann, B., Gregor, A., et al. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2007.09.044 · Cited by 323 · cited 2×
“Functional magnetic resonance imaging (fMRI) studies have found decreased activation in ventral striatal area during reward anticipation [Scheres et al., 2007; Ströhle et al., 2008; Plichta et al., 2009].”
BackgroundMedication treatment strategies in the MTA Study: relevance to clinicians and researchers
GREENHILL, L. L., ABIKOFF, H. B., ARNOLD, L. E., CANTWELL, D. P., CONNERS, C. K., ELLIOTT, G., HECHTMAN, L., HINSHAW, S. P., HOZA, B., JENSEN, P. S., et al. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199610000-00017 · Cited by 297
Plichta, M. M., Vasic, N., Wolf, R. C., Lesch, K.-P., Brummer, D., Jacob, C., Fallgatter, A. J., & Grön, G. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.07.008 · Cited by 272
Measured gene-by-environment interaction in relation to attention-deficit/hyperactivity disorder
Nigg, J., Nikolas, M., & Burt, S. A. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.01.025 · Cited by 259 · cited 1×
“The genetic etiology of ADHD involves interactions among multiple genetic variants and environmental conditions [Nigg et al., 2010].”
BackgroundHannestad, J., Gallezot, J.-D., Planeta-Wilson, B., Lin, S.-F., Williams, W. A., van Dyck, C. H., Malison, R. T., Carson, R. E., & Ding, Y.-S. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.017 · Cited by 236
The human dopamine D4 receptor repeat sequences modulate expression
Schoots, O., & Van Tol, H. H. M. (2003) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500208 · Cited by 213
NADDER, T. S., RUTTER, M., SILBERG, J. L., MAES, H. H., & EAVES, L. J. (2002) · Psychological Medicine · doi:10.1017/s0033291701004792 · Cited by 172
Pharmacogenetics of Methylphenidate Response in Preschoolers With ADHD
McGOUGH, J., McCRACKEN, J., SWANSON, J., RIDDLE, M., KOLLINS, S., GREENHILL, L., ABIKOFF, H., DAVIES, M., CHUANG, S., WIGAL, T., et al. (2006) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000235083.40285.08 · Cited by 126 · cited 1×
“These investigations suggest that the prediction of adverse events and medication tolerability would be a clinically relevant area of research, since adverse events are major impediments to long-term treatment adherence [McGough et al., 2006, 2009].”
BackgroundContribution of LPHN3 to the genetic susceptibility to ADHD in adulthood: a replication study
Ribasés, M., Ramos-Quiroga, J. A., Sánchez-Mora, C., Bosch, R., Richarte, V., Palomar, G., Gastaminza, X., Bielsa, A., Arcos-Burgos, M., Muenke, M., et al. (2011) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2010.00649.x · Cited by 119
Mick, E., Neale, B., Middleton, F. A., McGough, J. J., & Faraone, S. V. (2008) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30865 · Cited by 108
Methylphenidate Increases Cortical Excitability via Activation of Alpha-2 Noradrenergic Receptors
Andrews, G. D., & Lavin, A. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300818 · Cited by 101
Kambeitz, J., Romanos, M., & Ettinger, U. (2014) · The Pharmacogenomics Journal · doi:10.1038/tpj.2013.9 · Cited by 64
A cooperative interaction between LPHN3 and 11q doubles the risk for ADHD
Jain, M., Vélez, J. I., Acosta, M. T., Palacio, L. G., Balog, J., Roessler, E., Pineda, D., Londoño, A. C., Palacio, J. D., Arbelaez, A., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.59 · Cited by 57
Contini, V., Victor, M. M., Marques, F. Z. C., Bertuzzi, G. P., Salgado, C. A. I., Silva, K. L., Sousa, N. O., Grevet, E. H., Belmonte-de-Abreu, P., & Bau, C. H. D. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-009-0362-2 · Cited by 27 · cited 1×
“Nopharmacogenetic effect of theDAT1VNTRwas also reported in children [Langley et al., 2005; van der Meulen et al., 2005; Zeni et al., 2007; McGough et al., 2009] and in adults [Mick et al., 2006; Contini et al., 2010].”
BackgroundSelf-citation
Cited by
Subcommittee on Attention-Deficit/Hyperactivity Disorder, S. C. O. Q. I. A. M. (2011) · Pediatrics · doi:10.1542/peds.2011-2654 · Cited by 2,185
Wolraich, M. L., Hagan, J. F., Allan, C., Chan, E., Davison, D., Earls, M., Evans, S. W., Flinn, S. K., Froehlich, T., Frost, J., et al. (2019) · Pediatrics · doi:10.1542/peds.2019-2528 · Cited by 1,562
Treatment strategies for ADHD: an evidence-based guide to select optimal treatment
Caye, A., Swanson, J. M., Coghill, D., & Rohde, L. A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0116-3 · Cited by 303
Self-citationBonvicini, C., Faraone, S. V., & Scassellati, C. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.128 · Cited by 42
Gomez-Sanchez, C. I., Carballo, J. J., Riveiro-Alvarez, R., Soto-Insuga, V., Rodrigo, M., Mahillo-Fernandez, I., Abad-Santos, F., Dal-Ré, R., & Ayuso, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-10912-y · Cited by 24
Metadata
- Authors
- Bruxel, E. M., Akutagava‐Martins, G. C., Salatino‐Oliveira, A., Contini, V., Kieling, C., Hutz, M. H., & Rohde, L. A.
- Venue
- American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
- Publisher
- Wiley
- Published
- 2014-05-08
- Volume
- 165
- Issue
- 4
- Pages
- 263-282
- ISSN
- 1552-4841 (ISSN-L)
- 1552-485X
- OpenAlex
- W1975349850
- Cited by
- 51
- References
- 41
- FWCI
- 5.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.